Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thalidomide in cancer.

S Singhal1, J Mehta

  • 1Division of Hematology/Oncology, Northwestern University Medical School and The Robert H. Lurie Cancer Center of Northwestern University, Chicago, IL 60611, USA. s-singhal@northwestern.edu

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|March 22, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pan-Asia adapted ESMO Clinical Practice Guideline for the management of patients with newly diagnosed and relapsed epithelial ovarian cancer.

ESMO open·2025
Same author

Airway clearance therapy: experiences and perceptions of adults living with cystic fibrosis.

Disability and rehabilitation·2025
Same author

Right-sided meralgia paresthetica from lateral femoral cutaneous nerve neuroma.

Journal of ultrasound·2024
Same author

The non-steroidal anti-inflammatory drug salsalate provides safe and effective control of mucositis-unrelated pain during autologous and allogeneic hematopoietic stem cell transplantation.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2020
Same author

Shift working reduces operative experience for trauma and orthopaedic higher surgical trainees: a UK multicentre study.

Annals of the Royal College of Surgeons of England·2018
Same author

Evaluation of the reliability and validity of the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) in paediatric cutaneous lupus among paediatric dermatologists and rheumatologists.

The British journal of dermatology·2018
Same journal

Corrigendum to "Antidiabetic sitagliptin influences tissue regeneration by affecting progenitor cells" [Biomed. Pharmacother. 189 (2025) 118279].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum: "Zebrafish as a model to study inflammation: A tool for drug discovery" [Biomed. Pharmacother. 144 (2021) 112310].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Raloxifene and tamoxifen reshape the immunometabolic phenotype of TLRs-activated macrophages through AEBS inhibition and lysosomal stress.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Smart biomaterials in the dimensional revolution of bioprinting: From 2D to 6D for advanced biomedical applications.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

A trispecific GLP-1/anti-GIPR/FGF21 peptibody exhibits favorable metabolic effects in a diet-induced obesity model.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Malvidin and its glycosides in cancer treatment: Mechanisms, synergies and drug delivery strategies.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Thalidomide shows promise in treating various cancers, including myeloma, by modulating the immune system and inhibiting blood vessel growth. While effective, it carries side effects and is best used in clinical trials for most cancers.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Thalidomide possesses immunomodulatory and anti-angiogenic properties relevant to cancer treatment.
  • Its efficacy has been established in multiple myeloma, prompting investigation in other hematologic and solid tumors.

Purpose of the Study:

  • To review the efficacy and safety of thalidomide in various cancer types.
  • To assess the role of thalidomide in relapsed or refractory myeloma and other malignancies.

Main Methods:

  • Review of clinical trial data and published literature on thalidomide in cancer.
  • Analysis of response rates, synergistic effects, and adverse events across different cancer types.

Main Results:

  • Thalidomide shows significant response rates (30-50%) in myeloma, often synergizing with other therapies.

Related Experiment Videos

  • Positive outcomes, including reduced transfusion dependence, were observed in myelodysplastic syndromes and Kaposi's sarcoma.
  • Responses were noted in renal cell carcinoma, glioma, and colon cancer, particularly in combination regimens.

    • Conclusions:

    • Thalidomide is essential for relapsed/refractory myeloma and beneficial in clinical trials for other cancers.
    • Careful consideration of side effects, including neuropathy and thrombosis (especially with chemotherapy), is crucial.
    • Thalidomide can be considered as a single agent or in combination therapy when clinical trials or alternatives are unavailable.